The company also announced the appointment of seasoned medical device executive Robert Binney as Chief Executive Officer. Binney joins the company from Intersect ENT (NASDAQ: XENT), where he built a team of 200 employees and grew the company to over $100 million in annual revenue. As Chief Commercial Officer, Binney helped lead Intersect ENT from pre-FDA approval through a successful initial public offering and the launch of three products, while maintaining broad responsibility for the company’s global commercial strategy and execution. Prior to Intersect ENT, Binney worked in leadership roles with both startups and large medical device companies, including Boston Scientific (NYSE: BSX) and AccessClosure, now part of Cardinal Health.

“Alydia is poised to successfully address a serious condition that contributes significantly to maternal mortality in the United States and around the world, and I couldn’t be more excited to join this team during this critical time in the company’s evolution,” said Binney. “I believe in the potential of this unique technology to fill a growing clinical need in postpartum care, and I look forward to leading the company through its next phase of commercialization. We are proud that this esteemed group of investors recognizes the enormous opportunity Alydia represents in transforming innovations in women’s health.”